Ivacaftor Elpen (Ivacaftor)

Ivacaftor binds to the CFTR protein located on the surface of epithelial cells and stabilises its open channel configuration. This potentiation increases chloride ion transport across cell membranes, correcting the ion imbalance that characterises cystic fibrosis and leading to better hydration of airway secretions.

The dosage of ivacaftor is determined individually by a qualified prescriber based on the patient’s age, weight, mutation type, and clinical response. Healthcare professionals set the appropriate regimen and adjust it as needed during treatment.

The safety of ivacaftor in pregnancy and lactation has not been fully established, and the product label lists the pregnancy category as unknown. Clinicians should weigh potential benefits against possible risks and discuss options with the patient before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ivacaftor is a CFTR potentiator that directly enhances the gating function of the protein, whereas other classes such as correctors (e.g., lumacaftor) improve protein folding and trafficking. For patients with gating mutations, ivacaftor alone often provides greater clinical benefit than combination regimens that target different mechanisms.

Ivacaftor tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Ivacaftor is taken orally, usually with a meal to enhance absorption. The tablets are swallowed whole with water and should be taken exactly as prescribed by the treating physician.

Serious risks include significant elevations in liver enzymes, which require regular hepatic monitoring, and the development of cataracts, especially in younger patients. Rare but severe reactions such as Stevens‑Johnson syndrome, arrhythmias, or pulmonary haemorrhage also warrant immediate medical attention.

Ivacaftor is contraindicated in individuals with known hypersensitivity to ivacaftor or any of its excipients. Patients without a confirmed gating mutation of the CFTR gene are also not eligible for this therapy, as the drug’s mechanism targets that specific defect.